GGrantIndex
Sort

40,608 grants matching prostate cancer

Microbes and Human Malignancies

$486,661
James J Goedert · Division Of Cancer Epidemiology And Genetics · ZIA · FY2012 · CA

Understanding optimal delivery systems for cancer care

$486,648
David C Miller · University Of Michigan At Ann Arbor · R01 · FY2014 · CA

Long-Term Adverse Outcomes Among Rural Cancer Survivors in a Population-Based Cohort

$486,574
Mia Hashibe · University Of Utah · R01 · FY2021 · CA

CLINICAL TRIAL: THE SELENIUM AND VITAMIN E CHEMOPREVENTION TRIAL (SELECT)

$486,559
Rowan A Chlebowski · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · M01 · FY2010 · RR

NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma

$486,559
Xiao-Fan Wang · Duke University · R01 · FY2024 · CA

Genetic Epidemiology of Prostate Cancer

$486,482
Janet L Stanford · Fred Hutchinson Cancer Research Center · R01 · FY2007 · CA

Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation

$486,467
Srinivas Raghavan Viswanathan · Dana-Farber Cancer Inst · R01 · FY2024 · CA

Robot-Assisted MRI-Guided Prostate Biopsy

$486,361
Dan Stoianovici · Johns Hopkins University · RC1 · FY2010 · EB

Real time fine needle assessment of architectural heterogeneity in prostate cancer

$486,336
Guan Xu · University Of Michigan At Ann Arbor · R37 · FY2022 · CA

Discriminatory Mechanisms in Early-Onset and Lethal Prostate Cancer

$486,167
Barbara A Cohn · Public Health Institute · R01 · FY2024 · CA

RIPK2/MKK7/c-Myc Signaling as a Therapeutic Target in Prostate Cancer Metastasis

$486,109
Wei Yang · State University New York Stony Brook · R01 · FY2023 · CA

Validating and Extending the PROMIS Sexual Function Measure for Clinical Research

$486,108
Kevin P Weinfurt · Duke University · U01 · FY2012 · AR

Validating and Extending the PROMIS Sexual Function Measure for Clinical Research

$486,108
Kevin P Weinfurt · Duke University · U01 · FY2011 · AR

Clinical and Analytical Validation of Cancer Biomarkers

$486,000
Daniel W Chan · Johns Hopkins University · U24 · FY2017 · CA

NOVEL REGULATORS OF LINEAGE PLASTICITY IN CASTRATION-RESISTANT PROSTATE CANCER

$486,000
The Trustees Of Columbia University In The City Of New York · · FY2022 · Department of the Army

Clinical and Analytical Validation of Cancer Biomarkers

$486,000
Daniel W Chan · Johns Hopkins University · U24 · FY2020 · CA

ROLE OF ATAD2 IN PROSTATE CANCER BONE METASTASIS

$486,000
The Trustees Of Columbia University In The City Of New York · · FY2022 · Defense Health Agency

The Evaluation of Novel Therapeutics for Genitourinary Malignancies

$485,992
William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2011 · CA

Utilizing islet autoantibody signatures for precision medicine in type 2 diabetes

$485,960
Nisa M Maruthur · Johns Hopkins University · R01 · FY2022 · DK

Genetic Epidemiology of Prostate Cancer Aggressiveness

$485,892
John S Witte · University Of California, San Francisco · R01 · FY2011 · CA

Elucidating the molecular signaling of Cadmium Carcinogenesis

$485,844
Chendil Damodaran · Texas A&M University Health Science Ctr · R01 · FY2024 · ES

Mechanisms of targeting cellular self-renewal in glioblastoma

$485,837
Hatem Sabaawy · Rbhs -Cancer Institute Of New Jersey · R01 · FY2021 · CA

Acquisition of a Q-Exactive Plus Mass Spectrometer

$485,813
William T Jewell · University Of California At Davis · S10 · FY2019 · OD

LHRH Synthetic Peptide Vaccine for Prostate Cancer

$485,806
United Biomedical, Inc. · R44 · FY2003 · CA

TiO2 nanocomposites for Targeted Treatment and Imaging of Prostate cancer

$485,759
Gayle E Woloschak · Northwestern University At Chicago · U54 · FY2009 · CA